HeyJaredLisa Henderson
- Indexed articles, last 90 days
- 27
- Latest publication
- Sep 21, 2026
- Outlet visibility, for SCM
- Top 10M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Biopharma CFOs discuss finance strategies (opens the original)
Read excerpt
Read recent articles about the experts speaking at this week's conference. This week, Informa’s Finance and Accounting for Bioscience takes place in Boston, offering pharma professionals a place to learn, network, and discuss a variety of relvant topics. These include sessions on the 2027 finance outlook; controllership concerns; SEC and FASB presentations; and sessions for pre-commercial and commercial stage biopharma finance groups. Adam S. Mostafa, chief financial officer and head of business
Biopharma Companies Name Legal Leaders (opens the original)
Read excerpt
Four major biopharma companies bring in experienced legal and compliance leaders to strengthen their executive teams this month. Clinical-stage regenerative medicine biotech company developing personalized autologous cell therapies, Aspen Neuroscience, has appointed Jeff Boerneke as its general counsel and secretary. Boerneke comes to Aspen from Gossamer Bio, where he served as senior vice president, general counsel, and secretary. He was a member of the executive team and led all legal matters,
AstraZeneca settles Texas case for $34 million (opens the original)
Read excerpt
Monthly insights, guidance alerts and blogs from global life sciences law firms, compiled for you in one place. The Texas Attorney General’s office announced a nearly $34 million settlement with AstraZeneca Pharmaceuticals LP, resolving allegations that the company violated the Texas Health Care Program Fraud Prevention Act—the state equivalent of federal anti-kickback laws—through improper patient support services tied to 17 of its drugs. According to ArentFox Schiff partner Hillary M. Stemple
Nine drugmakers join US most-favored-nation plan (opens the original)
Read excerpt
The agreements cover treatments from hemophilia to cancer, with firms pledging nearly $20B in US manufacturing. Nine additional pharmaceutical manufacturers have entered into agreements to align US prescription drug prices with the lowest prices paid by other developed nations (most-favored-nation pricing). This brings the total number of participating manufacturers to 26, representing 89% of the branded drug market. The latest agreements are with Alcon, Astellas Pharma, BeOne Medicines, BridgeB
How the 340B program drifted from its mission (opens the original)
Read excerpt
New research traces how a 1992 fix for safety-net clinics became a compliance and litigation burden for pharma. The pharmaceutical industry’s almost 35-year relationship with 340B has reached levels of untenability. For those of you new to the pharma space, or to specific roles in pricing, compliance, litigation, or policy advocacy, or just want to understand the origins of 340B and how they impact the pharma space, you will want to read this open access article from The Milbank Quarterly. Congr
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 10M sites
For SCM, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.